drugset
Drugs / DMX-1002
last change Jan 2024 re-read 3 minutes ago

DMX-1002

Developed for
substance withdrawal syndrome
Investigated by
ERT: Clinical Trial Technology Solutions · Hammersmith Medicines Research · MAC Clinical Research · atai Therapeutics, Inc.

Trials 1

today NCT05029401 · Ph 1/2
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT05029401 Apr 2021 → Jan 2024 substance withdrawal syndrome atai Therapeutics, Inc. Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as DMX-1002 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05029401 ↗
Route Oral “A Study of Oral Ibogaine in Opioid Withdrawal” NCT05029401 ↗